Freestyle Libre Flash Glucose Monitoring System
Abbott Diabetes Care, Inc. · Decision date Sep 27, 2017
What did the FDA approve?
FDA records P160030 as an original PMA application. The recorded decision is approval, dated Sep 27, 2017.
FDA approval order statement
Approval for the Freestyle Libre Flash Glucose Monitoring System. The FreeStyle Libre Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions.The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Clinical Chemistry
- Decision date
- Sep 27, 2017
Regulatory record facts
- Identifier
- P160030
- Regulatory pathway
- Premarket approval application
- Applicant
- Abbott Diabetes Care, Inc.
- Product code
- PZE
- Decision code
- APPR
- Decision date
- Sep 27, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sensor, glucose, invasive, non-adjunctive, factory-calibrated, user-initiated.
- Applicant
- Abbott Diabetes Care, Inc.
- Product code
- PZE
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160030 received
Application receipt date recorded by FDA.
P160030 · FDA decision
APPR
P160030/S058 · Related supplement
Freestyle Libre Flash Glucose Monitoring System
Timeline entries are records held by MedtechLedger for P160030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Freestyle Libre Flash Glucose Monitoring SystemP160030/S058 | Abbott Diabetes Care, Inc. | PMA supplement | Sep 1, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Diabetes Care, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1360 S. Loop Dr., Alameda, CA, 94502
Sources and methodology
- Original FDA record: P160030
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records